Olistico Wealth LLC Sells 2,207 Shares of Novo Nordisk A/S $NVO

Olistico Wealth LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 74.5% in the second quarter, Holdings Channel reports. The institutional investor owned 755 shares of the company’s stock after selling 2,207 shares during the period. Olistico Wealth LLC’s holdings in Novo Nordisk A/S were worth $52,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Carolina Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 43.0% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 14,344 shares of the company’s stock valued at $990,000 after acquiring an additional 4,310 shares during the period. BridgePort Financial Solutions LLC grew its stake in Novo Nordisk A/S by 90.0% in the second quarter. BridgePort Financial Solutions LLC now owns 11,583 shares of the company’s stock valued at $799,000 after purchasing an additional 5,488 shares during the last quarter. Talbot Financial LLC raised its holdings in Novo Nordisk A/S by 22.7% in the second quarter. Talbot Financial LLC now owns 124,973 shares of the company’s stock worth $8,626,000 after purchasing an additional 23,133 shares in the last quarter. Clarius Group LLC lifted its position in shares of Novo Nordisk A/S by 12.7% during the second quarter. Clarius Group LLC now owns 14,970 shares of the company’s stock valued at $1,033,000 after buying an additional 1,689 shares during the last quarter. Finally, Signature Wealth Management Partners LLC bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at about $207,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $59.68 on Friday. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $120.56. The business’s 50 day moving average price is $54.92 and its 200 day moving average price is $63.73. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $266.45 billion, a P/E ratio of 16.39, a P/E/G ratio of 2.28 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is 22.53%.

Analyst Ratings Changes

Several brokerages have weighed in on NVO. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Novo Nordisk A/S in a research report on Saturday, September 27th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $77.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.